Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 49Breast 44Endocrine 25CNS 23Gastrointestinal 22NET 18Lymphoid 16Head & Neck 10Dermatologic 9Tumor-Agnostic 8Thoracic 8Sarcoma 8Other hematologic neoplasm 8Gynecologic 8Other solid neoplasm 4Plasma cell 3Other 1Myeloid 1

Conditions

Somatostatinoma 1Mucositis 1Insulinoma 1Glucagonoma 1Gastrinoma 1Carcinoma, Renal Cell 1Carcinoma, Islet Cell 1Breast Neoplasms 1

Interventions

Radiotherapy 9naloxegol 7Metformin 7Surveys and Questionnaires 6Cisplatin 6Exenatide 4Vitamin D 3Sugars 3Fibroblast Growth Factor 7 3Water 2Therapeutics 2Testosterone 2Resistance Training 2Radiation 2Nutrition Assessment 2Methods 2Low-Level Light Therapy 2Injections 2Fentanyl 2Drug Therapy 2Dexamethasone 2Cryotherapy 2Calcium Dobesilate 2Anastrozole 2prucalopride 1peppermint oil 1penclomedine 1pegfilgrastim 1oxycodone-acetaminophen 1methylnaltrexone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Everolimus × Other × Clear all
NCT02273752 2017-02-03

Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer

Emory University

Phase 2 Terminated
2 enrolled 5 charts
BreastEndocrineGenitourinaryOther

Breast Neoplasms, Carcinoma, Renal Cell, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡